Develops ophthalmic drugs for the treatment of various eye disorders, focusing on both front and back of the eye diseases.
Ocuphire Pharma, Inc. is a dynamic clinical-stage ophthalmic biopharmaceutical firm dedicated to advancing innovative therapies for refractive and retinal eye disorders. The company's flagship product candidate, Nyxol eye drops, represents a significant breakthrough as a once-daily preservative-free formulation of phentolamine mesylate. Currently, Nyxol is undergoing Phase III clinical trials for dim light or night vision disturbances, Phase 2b trials for pharmacologically induced mydriasis, and has completed Phase 2 VEGA-1 trials for presbyopia. Ocuphire Pharma is also actively developing APX3330, an oral tablet administered twice daily, designed to target pathways relevant to retinal and choroidal vascular diseases like diabetic retinopathy and diabetic macular edema. Additionally, the company is advancing APX2009 and APX2014, second-generation preclinical product candidates and analogs derived from APX3330, further bolstering its robust pipeline of innovative ophthalmic treatments.
Headquartered in Farmington Hills, Michigan, Ocuphire Pharma strategically positions itself at the forefront of ophthalmic innovation in the United States. The company's location within a thriving biopharmaceutical hub provides access to cutting-edge research, clinical expertise, and strategic partnerships essential for advancing novel therapies. With a strong commitment to addressing unmet medical needs in eye care, Ocuphire Pharma continues to expand its portfolio and explore new avenues for improving vision health globally.
Driven by a mission to enhance patient outcomes and redefine standards of care in ophthalmology, Ocuphire Pharma remains steadfast in its pursuit of transformative treatments. Through ongoing research and development initiatives, the company strives to bring meaningful advancements to the field, aiming to improve the quality of life for individuals affected by refractive and retinal eye disorders.